DBV Technologies S.A. (DBVT) Stock Analysis
Healthcare · Biotechnology
Hold if already holding. Not a fresh buy at $15.86, but acceptable to hold if already in. Reason: Market cap $0.95B below $1B minimum.
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for... Read more
Hold if already holding. Not a fresh buy at $15.86, but acceptable to hold if already in. Reason: Market cap $0.95B below $1B minimum. Chart setup: No clear chart pattern; technical signals are mixed. Market cap $0.95B below $1B minimum. Not in investable universe. Score 5.2/10, moderate confidence.
Passes 7/8 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity 50d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum. Suitability: aggressive.
Recent developments
updated 2026-06-09Recent Developments — DBV Technologies S.A.
Latest news
- NEWS DBV Technologies To Present New Data From VITESSE Study And Preview Recently Initiated THRIVE Study At EAACI Congress 20 — benzinga Jun 8, 2026
- NEWS DBV Technologies Starts Infant Study of Peanut Allergy Patch — benzinga Jun 3, 2026
- NEWS Guggenheim Reiterates Buy on DBV Technologies, Maintains $51 Price Target — benzinga May 4, 2026 positive
- NEWS Citizens Maintains Market Outperform on DBV Technologies, Raises Price Target to $55 — benzinga May 1, 2026 positive
- NEWS DBV Technologies Q1 EPS $(0.11) Beats $(0.12) Estimate, Sales $900.000K Miss $1.268M Estimate — benzinga Apr 30, 2026 neutral
Generated 2026-06-09T22:06:37Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
5 floor-breakers·1 ceiling hit
Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static
Volatile — 5.4% daily ATR makes tight stops impractical. Position-size conservatively.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Quality below the gate floor. Component breakdown shows what dragged the score down.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $15.86, but acceptable to hold if already in. Reason: Market cap $0.95B below $1B minimum. Chart setup: No clear chart pattern; technical signals are mixed. Market cap $0.95B below $1B minimum. Not in investable universe. Target $35.12 (+121.4%), stop $15.36 (−3.3%), A.R:R 11.2:1. Score 5.2/10, moderate confidence.
Take-profit target: $35.12 (+121.6% upside). Target $35.12 (+121.4%), stop $15.36 (−3.3%), A.R:R 11.2:1. Stop-loss: $15.36.
Market cap $0.95B below $1B minimum.
DBV Technologies S.A. trades at a P/E of N/A (forward -32.9). TrendMatrix value score: 9.0/10. Verdict: Hold.
8 analysts cover DBVT with a consensus score of 4.0/5. Average price target: $40.
What does DBV Technologies S.A. do?DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of...
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs include celiac disease. In addition, the company develops Viaskin technology platform, a platform to potentially treat food allergy. It has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Châtillon, France.